Novartis AG (NVSEF) Operating income 2016–2025
Novartis AG (NVSEF) annual operating income history from SEC filings — each fiscal year as reported.
$17.6BFY2025 · since FY2016: $8.3B → $17.6B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $17.6B | +21.3% |
| FY2024 | $14.5B | +48.9% |
| FY2023 | $9.8B | +22.9% |
| FY2022 | $7.9B | -21.0% |
| FY2021 | $10.1B | -0.9% |
| FY2020 | $10.2B | +11.7% |
| FY2019 | $9.1B | +8.1% |
| FY2018 | $8.4B | -3.4% |
| FY2017 | $8.7B | +5.2% |
| FY2016 | $8.3B | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NVSEF financial trends
NVSEF RevenueNVSEF Net incomeNVSEF Net marginNVSEF Gross profitNVSEF Gross marginNVSEF Operating marginNVSEF Operating cash flowNVSEF Free cash flowNVSEF Capital expendituresNVSEF Return on equityNVSEF Stock buybacksNVSEF Dividends paidNVSEF Total assetsNVSEF Total liabilitiesNVSEF Shareholders’ equityNVSEF overview →